PUBLICATIONS

pdf

2026

POSTER PRESENTATION AAN 2026: Expected Centiloid Values for Patients with Positive Visual Reads of Amyloid …

Download

pdf

2026

PLATFORM PRESENTATION ADPD 2026: Enhanced Brain Delivery of Sabirnetug After Fusion with an Anti-Transferrin Receptor …

Download

pdf

2026

POSTER PRESENTATION ADPD 2026: Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with …

Download

pdf

2026

POSTER PRESENTATION ADPD 2026: Sabirnetug Biomarker Treatment Responses: Exploratory Evaluation of the CNS Disease Panel …

Download

pdf

2025

POSTER PRESENTATION CTAD 2025: Fusing Transferrin Receptor Binders to the AβO-targeting Antibody Sabirnetug Achieves Increased …

Download

pdf

2025

POSTER PRESENTATION CTAD 2025: ALTITUDE-AD: Recruitment strategies for a global phase 2 trial of sabirnetug …

Download

70161

2025

MANUSCRIPT 2025 TRCI: Recruitment and eligibility in a Phase 1 early Alzheimer’s disease trial of …

Download

pdf

2025

POSTER PRESENTATION AAIC 2025: Sabirnetug shows superior selectivity for Aβ oligomers over monomer, a differentiated …

Download

pdf

2025

POSTER PRESENTATION AAIC 2025: ALTITUDE-AD: Cost savings using a pTau217 screening assay in an ongoing …

Download

pdf

2025

POSTER PRESENTATION AAN 2025: INTERCEPT-AD Biomarker Results: Early effect of sabirnetug treatment on synaptic biomarkers …

Download

pdf

2025

PLATFORM PRESENTATION 2025 AAN: ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in …

Download

pdf

2025

POSTER PRESENTATION 2025 ADPD: Utility of Human iPSC-derived Neuronal Model for Evaluating Synaptic Binding of …

Download

pdf

2025

POSTER PRESENTATION 2025 ADPD: Preparing Stable Monomeric Aβ to Assess AβO Selectivity Assays

Download

pdf

2025

PLATFORM PRESENTATION ADPD 2025: ALTITUDE-AD: Use of a Validated Plasma pTau217 Assay to Screen Potential …

Download

pdf

2025

PLATFORM PRESENTATION APDD 2025 Summit: Sabirnetug overview and use of a pTau217 Assay as a …

Download

www

2025

MANUSCRIPT JPAD 2025: Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase …

Download

www

2025

MANUSCRIPT JPAD 2025: INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild …

Download

pdf

2024

PLATFORM PRESENTATION CTAD 2024: ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants …

Download

pdf

2024

POSTER PRESENTATION AAIC 2024: INTERCEPT-AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative …

Download

pdf

2024

POSTER PRESENTATION AAIC 2024: Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase …

Download

pdf

2024

POSTER PRESENTATION AAIC 2024: INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total …

Download

pdf

2024

POSTER PRESENTATION AAIC 2024: INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial …

Download

pdf

2024

PLATFORM PRESENTATION ADPD 2024: Sabirnetug (ACU193) Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study …

Download

pdf

2024

POSTER PRESENTATION ADPD 2024: Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring …

Download

pdf

2024

PLATFORM PRESENTATION AAN 2024: A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, …

Download

pdf

2024

POSTER PRESENTATION AAN 2024: A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, …

Download

pdf

2023

POSTER PRESENTATION CTAD 2023: Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A …

Download

pdf

2023

POSTER PRESENTATION ADPD 2023: Binding of Soluble Amyloid Beta Oligomer Species to Human IPSC-derived …

Download

pdf

2023

PLATFORM PRESENTATION AAIC 2023: Topline results of INTERCEPT-AD: A phase I trial of Aβ …

Download

pdf

2023

POSTER PRESENTATION CTAD 2023: INTERCEPT-AD phase 1 insights and findings from the investigation of …

Download

pdf

2023

POSTER PRESENTATION CTAD 2023: INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease.

Download

pdf

2023

POSTER PRESENTATION CTAD 2023: Incorporating the Study Participant’s Voice into Early Development of ACU193 …

Download

pdf

2023

POSTER PRESENTATION CTAD 2023: ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive …

Download

93

2022

MANUSCRIPT JPAD 2022: ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development …

Download

848215

2022

MANUSCRIPT Frontiers in Neuroscience 2022: ACU193: An Immunotherapeutic Poised to Test the Amyloid β …

Download

pdf

2022

POSTER PRESENTATION AAIC 2022: Preparation and qualification of soluble AβOs for use in bioanalytical …

Download

pdf

2022

POSTER PRESENTATION CTAD 2022: Critical evaluation and comparison of biomarker values in commercial CSF …

Download

pdf

2021

PLATFORM PRESENTATION CTAD 2021: Phase 1 trial design for ACU193, a monoclonal antibody that …

Download

pdf

2019

POSTER PRESENTATION AAIC 2019: Soluble Aβ-Oligomer–Selective Antibody ACU3B3 Reduces Amyloid Pathology & Improves Multiple …

Download

pdf

2019

POSTER PRESENTATION CTAD 2019: Synaptic intervention in Alzheimer’s disease: soluble Aβ oligomer directed ACU193 monoclonal …

Download

pdf

2017

POSTER PRESENTATION SfN 2017: Oligomeric Ab-induced neuronal toxicity is attenuated by ADDL-specific antibodies in …

Download

pdf

2014

POSTER PRESENTATION SfN 2014: Soluble Aβ-oligomer-selective Antibody ACU-3B3 Reduces Amyloid Pathology and Improves Multiple Behavioral …

Download

pdf

2014

POSTER PRESENTATION SfN 2014: Passive immunization with the anti-Aβ oligomer antibody ACU-3B3 improves behavioral …

Download

We are dedicated to translating scientific breakthroughs into effective treatments for people with Alzheimer’s disease through cutting-edge research and comprehensive clinical trials.

2026

2025

2024

2023

2022

2021

2019

2017

2014